ToxStrategies, Inc., Rancho Santa Margarita, CA 92688, United States.
Chemosphere. 2012 Oct;89(5):487-93. doi: 10.1016/j.chemosphere.2012.04.065. Epub 2012 Jun 8.
Reduction of hexavalent chromium (Cr(VI)) to trivalent chromium (Cr(III)) in the stomach prior to absorption is a well-recognized detoxification process thought to limit the toxicity of ingested Cr(VI). However, administration of high concentrations of Cr(VI) in drinking water cause mouse small intestinal tumors, and quantitative measures of Cr(VI) reduction rate and capacity for rodent stomach contents are needed for interspecies extrapolation using physiologically-based toxicokinetic (PBTK) models. Ex vivo studies using stomach contents of rats and mice were conducted to quantify Cr(VI) reduction rate and capacity for loading rates (1-400 mg Cr(VI)L(-1) stomach contents) in the range of recent bioassays. Cr(VI) reduction was measured with speciated isotope dilution mass spectrometry to quantify dynamic Cr(VI) and Cr(III) concentrations in stomach contents at select time points over 1 h. Cr(VI) reduction followed mixed second-order kinetics, dependent upon concentrations of both Cr(VI) and the native reducing agents. Approximately 16 mg Cr(VI)-equivalents of reducing capacity per L of fed stomach contents (containing gastric secretions, saliva, water and food) was found for both species. The second-order rate constants were 0.2 and 0.3 L mg(-1) h(-1) for mice and rats, respectively. These findings support that, at the doses that caused cancer in the mouse small intestine (≥ 20 mg Cr(VI)L(-1) in drinking water), the reducing capacity of stomach contents was likely exceeded. Thus, for extrapolation of target tissue dose in risk assessment, PBTK models are necessary to account for competing kinetic rates including second order capacity-limited reduction of Cr(VI) to Cr(III).
在吸收前将六价铬(Cr(VI))还原为三价铬(Cr(III))是一种公认的解毒过程,据认为可限制摄入的 Cr(VI)的毒性。然而,饮用水中高浓度的 Cr(VI)会导致小鼠小肠肿瘤,并且需要定量测量啮齿动物胃内容物中 Cr(VI)的还原率和还原能力,以便使用基于生理的毒代动力学(PBTK)模型进行种间外推。使用大鼠和小鼠的胃内容物进行了离体研究,以量化在最近的生物测定范围内(1-400 mg Cr(VI)L(-1)胃内容物)的 Cr(VI)还原率和负载率(1-400 mg Cr(VI)L(-1)胃内容物)的能力。通过种特异性同位素稀释质谱法测量 Cr(VI)还原,以在 1 小时的选定时间点定量胃内容物中动态 Cr(VI)和 Cr(III)浓度。Cr(VI)还原遵循混合二级动力学,取决于 Cr(VI)和天然还原剂的浓度。对于这两个物种,每升喂食的胃内容物(包含胃分泌物、唾液、水和食物)中发现约 16 mg Cr(VI)当量的还原能力。对于小鼠和大鼠,二级速率常数分别为 0.2 和 0.3 L mg(-1) h(-1)。这些发现表明,在导致小鼠小肠癌症的剂量(饮用水中≥20 mg Cr(VI)L(-1))下,胃内容物的还原能力可能已经超过。因此,对于风险评估中的靶组织剂量外推,PBTK 模型是必要的,以考虑包括第二级容量限制的 Cr(VI)还原为 Cr(III)的竞争动力学速率。